

PRIOR AUTHORIZATION POLICY

POLICY: Oncology – Tabrecta Prior Authorization Policy

- Tabrecta® (capmatinib tablets – Novartis)

REVIEW DATE: 02/01/2023

OVERVIEW

Tabrecta, a kinase inhibitor, is indicated for the treatment of adults with metastatic **non-small cell lung cancer (NSCLC)** whose tumors have a mutation that leads to mesenchymal-epithelial transition (*MET*) exon 14 skipping as detected by an FDA-approved test.¹

Guidelines

The National Comprehensive Cancer Network (NCCN) NSCLC guidelines (version 1.2023 – December 22, 2022) recommend Tabrecta as a first-line or subsequent line treatment option for patients with advanced or metastatic NSCLC who are positive for *MET* exon 14 skipping mutations or high-level *MET* amplification.²

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Tabrecta. All approvals are provided for the duration noted below.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Tabrecta is recommended in those who meet the following criteria:

FDA-Approved Indication

- 1. Non-Small Cell Lung Cancer.** Approve for 1 year if the patient meets the following criteria (A, B, and C):
 - A) Patient is ≥ 18 years of age; AND
 - B) Patient has advanced or metastatic disease; AND
 - C) Patient meets one of the following criteria (i or ii):
 - i. Patient has mesenchymal epithelial transition (*MET*) exon 14 skipping mutations as detected by an approved test; OR
 - ii. Patient has high-level *MET* amplification as detected by an approved test.

02/01/2023

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Tabrecta is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Tabrecta® tablets [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2022.
2. The NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (version 1.2023 – December 22, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org/>. Accessed on January 27, 2023.